#1 Clinical Trials Search in Europe

Nilotinib

Nilotinib, also known by its brand name Tasigna, is a targeted cancer drug that has shown promise in treating various conditions in clinical trials. This article explores how nilotinib is being studied to potentially treat chronic myeloid leukemia (CML), gastrointestinal stromal tumors (GIST), neurofibromatosis, and other disorders. We’ll examine the latest research on nilotinib’s effectiveness, safety, and potential new applications.

Table of Contents

What is Nilotinib?

Nilotinib is a medication used to treat certain types of cancer. It’s also known by its brand names Tasigna[1] and AMN107[2]. Nilotinib belongs to a class of drugs called tyrosine kinase inhibitors (TKIs), which work by blocking specific proteins that contribute to cancer growth[3].

What Conditions Does Nilotinib Treat?

Nilotinib is primarily used to treat several conditions:

  • Chronic Myeloid Leukemia (CML): This is a type of blood cancer where the body produces too many abnormal white blood cells. Nilotinib is used for CML in various phases, including chronic phase, accelerated phase, and blast crisis[4].
  • Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL): This is another type of blood cancer affecting lymphoid cells. Nilotinib is used in patients who have not responded to other treatments[4].
  • Gastrointestinal Stromal Tumors (GIST): These are rare tumors that occur in the digestive tract. Nilotinib is being studied for use in patients with GIST who have not responded to or cannot tolerate other treatments[5].
  • Pigmented Villonodular Synovitis (PVNS): This is a rare, non-cancerous but potentially aggressive condition affecting the joints. Nilotinib is being investigated as a treatment for PVNS in cases where surgery is not possible[6].

How Does Nilotinib Work?

Nilotinib works by targeting specific proteins in cancer cells:

  • BCR-ABL protein: In CML and Ph+ ALL, nilotinib blocks the BCR-ABL protein, which is responsible for the uncontrolled growth of abnormal white blood cells[3].
  • Other proteins: Nilotinib also inhibits proteins called c-Kit, PDGFR-alpha, and PDGFR-beta, which are involved in the growth of certain types of cancer cells[7].

By blocking these proteins, nilotinib helps to slow or stop the growth of cancer cells, potentially leading to remission of the disease.

Dosage and Administration

Nilotinib is typically taken orally in capsule form. The dosage can vary depending on the condition being treated and the patient’s response to the medication. Some common dosages include:

  • 400 mg twice daily for CML and GIST[5]
  • 300 mg twice daily for some CML patients[2]

It’s important to note that nilotinib should be taken on an empty stomach. Patients should not eat for at least 2 hours before and 1 hour after taking the medication[6]. This is because food can affect how the body absorbs the drug.

Potential Side Effects

Like all medications, nilotinib can cause side effects. Some common side effects may include:

  • Nausea and vomiting
  • Fatigue
  • Headache
  • Skin rash
  • Changes in blood cell counts

More serious side effects can occur, such as heart problems or liver issues. It’s important to discuss all potential side effects with your healthcare provider[1].

Current Clinical Trials

Nilotinib is being studied in various clinical trials to explore its effectiveness in different conditions and treatment strategies. Some ongoing studies include:

  • Combining nilotinib with other drugs like ruxolitinib for CML treatment[4]
  • Using nilotinib in combination with chemotherapy for children with certain brain tumors[7]
  • Investigating nilotinib as a treatment for PVNS[6]

Combination Therapies

Researchers are exploring the use of nilotinib in combination with other drugs to potentially improve treatment outcomes. Some combinations being studied include:

  • Nilotinib with Ruxolitinib: This combination is being investigated for CML patients who have not responded well to other treatments[4].
  • Nilotinib with Imatinib: This combination is being studied for patients with advanced GIST who have progressed on high-dose imatinib alone[8].
  • Nilotinib with Vinblastine: This combination is being explored for children with certain types of brain tumors[7].

These combination therapies aim to improve the effectiveness of treatment and overcome drug resistance in some patients.

Aspect Details
Main Conditions Studied Chronic Myeloid Leukemia (CML), Gastrointestinal Stromal Tumors (GIST), Neurofibromatosis, Pigmented Villonodular Synovitis (PVNS)
Typical Dosing 300-400 mg twice daily, adjusted based on patient response and tolerability
Key Efficacy Measures Molecular response rates, cytogenetic response, progression-free survival
Safety Monitoring Regular blood tests, ECG monitoring, assessment of adverse events
Potential New Applications Cerebellar ataxia, combination therapy with other drugs
Long-term Follow-up Some studies tracking patients for up to 5 years to assess long-term outcomes

FAQ

  • What is nilotinib and how does it work? Nilotinib is a targeted cancer drug that works by blocking certain proteins that cancer cells need to grow. It is mainly used to treat a type of blood cancer called chronic myeloid leukemia (CML).
  • What conditions is nilotinib being studied for in clinical trials? Clinical trials are exploring nilotinib for chronic myeloid leukemia, gastrointestinal stromal tumors, neurofibromatosis, pigmented villonodular synovitis, and cerebellar ataxia.
  • How is nilotinib typically taken? Nilotinib is usually taken as oral capsules, often twice daily. The exact dose depends on the condition being treated and may be adjusted by the doctor based on how well it's working.
  • What are some potential side effects of nilotinib? Common side effects may include nausea, fatigue, headache, and skin rash. More serious side effects can occur but are less common. Patients should report any unusual symptoms to their doctor.
  • How long do patients typically stay on nilotinib treatment? Treatment duration varies depending on the condition and how well the patient responds. Some patients may take nilotinib for many months or even years if it's working well and side effects are manageable.

Ongoing Clinical Trials on Nilotinib

  • Long-Term Safety Study of Asciminib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Bulgaria Czechia Denmark France Germany +8

  • Study for Adults with Chronic Myeloid Leukemia Using Asciminib Alone or with Nilotinib

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy Spain

  • Evaluation of drug combination therapy (olaparib, nilotinib, tremelimumab, and durvalumab) for patients with advanced or metastatic solid tumors

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Effectiveness of Entrectinib and Other Drug Combinations for Patients with Advanced Solid Tumors, Multiple Myeloma, or Non-Hodgkin Lymphoma

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on Stopping Nilotinib for Chronic Myeloid Leukemia Patients After Previous Unsuccessful Attempts to Stop Tyrosine Kinase Inhibitors

    Not yet recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on the Bioavailability of Nilotinib in Healthy Individuals with Chronic Myelogenous Leukemia (CML)

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Portugal

  • Study on Stopping Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients: Comparing Dasatinib, Imatinib, Nilotinib, and Bosutinib Strategies

    Not recruiting

    3 1 1 1
    Investigated drugs:
    France

  • Study of treatment discontinuation with nilotinib and asciminib in adults with chronic myeloid leukemia to achieve treatment-free remission

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Italy

  • Study on Stopping Nilotinib, Imatinib, and Dasatinib in Patients with Chronic Myeloid Leukemia in Deep Remission

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia

  • Study on the Effectiveness of Asciminib and Imatinib for Patients with Chronic Myelogenous Leukemia Not Responding to Imatinib

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Austria Czechia France Italy Spain

Glossary

  • Chronic Myeloid Leukemia (CML): A type of blood cancer that starts in certain blood-forming cells of the bone marrow and invades the blood.
  • Gastrointestinal Stromal Tumor (GIST): A type of tumor that occurs in the digestive tract, most commonly in the stomach or small intestine.
  • Neurofibromatosis: A genetic disorder that causes tumors to form on nerve tissue, which can affect the skin, brain, and other parts of the body.
  • Pigmented Villonodular Synovitis (PVNS): A rare condition causing the joint lining to become inflamed and overgrow, typically affecting the knee or hip.
  • Cerebellar Ataxia: A neurological condition affecting the cerebellum that can cause problems with balance, coordination, and speech.
  • Molecular Response: A measure of how well a treatment is working at the molecular level, often used in leukemia treatment.
  • BCR-ABL: An abnormal protein found in leukemia cells of patients with chronic myeloid leukemia.
  • Cytogenetic Response: A measure of how well a treatment is working based on examining chromosomes in cancer cells.
  • Progression-Free Survival: The length of time during and after treatment that a patient lives without the disease getting worse.
  • RECIST Criteria: Response Evaluation Criteria in Solid Tumors – a set of rules used to measure how well a cancer patient responds to treatment.

References

  1. https://clinicaltrials.gov/study/NCT00980018
  2. https://clinicaltrials.gov/study/NCT03874858
  3. https://clinicaltrials.gov/study/NCT03654768
  4. https://clinicaltrials.gov/study/NCT01914484
  5. https://clinicaltrials.gov/study/NCT00633295
  6. https://clinicaltrials.gov/study/NCT01261429
  7. https://clinicaltrials.gov/study/NCT01884922
  8. https://clinicaltrials.gov/study/NCT01089595